UGT1A1*28基因多态性与伊立替康疗效和毒副作用相关性研究进展  

Association of UGT1A1*28 polymorphism with the efficacy and toxicity of irinotecan chemotherapy

作　　者：赵荣荣[1,2] 牛作兴[1] 

机构地区：[1]山东省肿瘤医院内四病区,山东济南250117 [2]济南大学.山东省医学科学院医学与生命科学学院,山东济南250200

出　　处：《中华肿瘤防治杂志》2013年第9期717-720,共4页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:总结UGT1A1*28基因多态性与伊立替康(CPT-11)疗效及毒性的相关性。方法:应用PubMed及CNKI期刊全文数据库检索系统,以"UGT1A1*28基因多态性、CPT-11、疗效和毒性"为关键词,检索2000-01-2012-05相关文献,共检索到英文文献208篇和中文文献8篇。纳入标准:1)CPT-11的体内代谢;2)UGT1A1*28基因型特点;3)一线化疗;4)UGT1A1*28基因多态性与疗效和毒性的关系。根据纳入标准符合分析的文献28篇。结果:CPT-11的体内代谢与尿苷二磷酸葡萄糖醛酸转移酶家族(UGTS)密切相关,UGTS的表达由UGT1A1基因位点决定。UGT1A1*28为7个TA重复序列,包括纯合型(TA7/TA7)和杂合型(TA6/TA7),随着TA重复序列数目的增加,CPT-11相关毒性增加。多数研究表明,UGT1A1*28基因多态性与CPT-11化疗疗效无关。在欧美人群中,UGT1A1*28与CPT-11的剂量限制性毒性,即延迟性腹泻和中性粒细胞减少有明显相关性;在亚洲人群中,UGT1A1*28与腹泻的关系更为密切。结论:UGT1A1*28基因多态性具有种族差异,今后尚需开展大规模的前瞻性研究来验证UGT1A1*28基因多态性与CPT-11疗效和毒性的关系,从而指导个体化治疗。OBJECTIVE：To sum up the association of UGTIA1 ＊ 28 polymorphism with the efficacy and toxicity of irinotecan. METHODS：Totally 208 English articles and 8 Chinese papers were searched by ＂UGTIA1 ＊ 28 polymorphism,irinotecan, clinical efficacy,toxicity＂ as keywords in PubMed and CNKI database from 2000-01 to 2012-05. Totally 28 papers were selected and analyzed according to the inclusion criteria as follows.. 1）Irinotecan metabolism in the body; 2） Feature of UGT1A1 ＊ 28 ; 3） First-line chemotherapy ; 4） Association of UGT1 A1 ＊ 28 polymorphism with the efficacy and toxicity. RESULTS.. Irinotecan metabolism is associated with Uridine diphosphate glucuronosyl transferase 1,which was encoded by UGT1A1 gene. UGTIA1 ＊ 28 polymorphism consists of TA6/TA7 and TA7/TAT. With the number of TA incresing,the toxicity of irinotecan is more serious. Majority researches show that UGT1A1 ＊ 28 polymorphism is un- correlated with clinical efficacy of irinotecan. UGT1A1 ＊ 28 polymorphism is associated with severe neutropenia and diarrhea caused by irinotecan in Europeans and Americans,while associated with severe diarrhea in Asians. CONCLUSIONS： UGT1A1 ＊ 28 polymorphism has racial differences. Large scale and prospective research are required to verify association of UGT1A1 ＊28 polymorphism with the efficacy and toxicity of irinotecan to individualise therapy.

关 键 词：UGT1A1＊28基因多态性 伊立替康 疗效 毒性 综述文献 

分 类 号：R730.5[医药卫生—肿瘤]